NCT02344368

Brief Summary

Despite the fact that oral sucrose is the most frequently studied non-pharmacological intervention for procedural pain relief in infants, there is a paucity of data on the minimal effective dose. The aim of this study is to find the minimal effective dose of sucrose to reduce pain during a single venous blood sampling procedure.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable pain

Timeline
Completed

Started Jan 2015

Typical duration for not_applicable pain

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

January 16, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 26, 2015

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

June 4, 2020

Status Verified

July 1, 2016

Enrollment Period

1.4 years

First QC Date

January 16, 2015

Last Update Submit

June 2, 2020

Conditions

Keywords

SucroseAnesthesiaBlood specimen collectionInjections, Intravenous

Outcome Measures

Primary Outcomes (1)

  • pain

    assessed by Premature Infant Pain Profile-Revised (PIPP-R). Pain score related to the blood sampling will be performed two times: at skin puncture and immediately after the needle has been removed

    1 week

Study Arms (2)

0.2 ml sucrose

EXPERIMENTAL

on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling

Other: 0.2 ml sucrose 25%Other: 0.5 ml sucrose 25%

0.5 ml sucrose

EXPERIMENTAL

on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling

Other: 0.2 ml sucrose 25%Other: 0.5 ml sucrose 25%

Interventions

Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling

0.2 ml sucrose0.5 ml sucrose

Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling

0.2 ml sucrose0.5 ml sucrose

Eligibility Criteria

AgeUp to 8 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • born preterm
  • more than 1000 gram

You may not qualify if:

  • severe intraventricular hemorrhage
  • cerebral malformations
  • other malformations requiring surgery
  • medication that may impair pain expression (opioids, paracetamol, sedatives)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

St Olavs Hospital

Trondheim, Norway

Location

Lower Umfolozi Rigional War Memorial Hospital, NICU

Empangeni, South Africa

Location

Related Publications (1)

  • Kristoffersen L, Malahleha M, Duze Z, Tegnander E, Kapongo N, Stoen R, Follestad T, Eik-Nes SH, Bergseng H. Randomised controlled trial showed that neonates received better pain relief from a higher dose of sucrose during venepuncture. Acta Paediatr. 2018 Dec;107(12):2071-2078. doi: 10.1111/apa.14567. Epub 2018 Oct 2.

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Håkon Bergseng, MD PhD

    Norwegian University of Science and Technology

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2015

First Posted

January 26, 2015

Study Start

January 1, 2015

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

June 4, 2020

Record last verified: 2016-07

Locations